Skip to main content
. 2017 Feb 20;8(15):24506–24517. doi: 10.18632/oncotarget.15534

Figure 6. Pirfenidone suppresses human COL1A1, HAS2, HAS3, COL3, TGFB1 and FN1 gene expression levels.

Figure 6

Real-time PCR gene expression analysis for the quantification of human collagen I, (hCOL1A1), hyaluronan synthase 1 (hHAS1), hyaluronan synthase 2 (hHAS2), hyaluronan synthase 3 (hHAS3), periostin (hPOSTN), collagen 3 (hCOL3A1), collagen 4 (hCOL4A1), transforming growth factor-beta 1 (hTGFβ1), vimentin (hVIM), fibronectin (hFN1), and lysyl oxidase (hLOX) mRNA levels in control-treated compared to Pirfenidone-treated MCF10CA1a tumors. Data indicate that Pirfenidone downregulates expression of COL1A1, HAS2, HAS3, COL3A1, TGFB1 and FN1 genes. Data represent the average expression of each gene normalized to beta-actin from at least 3 independent experiments from 5 control and 5 Pirfenidone-treated tumors. Asterisks indicate statistically significant differences between compared groups (p < 0.05).